Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Atherosclerosis - Pipeline Review, H1 2015
Publication Date Jun 2015
Product Type Report
Pages 276
Single User License help $ 2000.00
Site User License help $ 4000.00
Corporate User License help $ 6000.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Atherosclerosis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Atherosclerosis - Pipeline Review, H1 2015’, provides an overview of the Atherosclerosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atherosclerosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Atherosclerosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Atherosclerosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Atherosclerosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Ache Laboratorios Farmaceuticos advanceCor GmbH AFFiRiS AG Arisaph Pharmaceuticals, Inc. Artery Therapeutics, Inc. AstraZeneca Plc Athera Biotechnologies AB AtheroNova Inc. AuraSense Therapeutics, LLC Bayer AG Bridge Bioresearch Plc Campus Technologies Freiburg G Cardax Pharmaceuticals, Inc. ChemoCentryx, Inc. CohBar Inc. DoNatur GmbH Dr. Reddy's Laboratories Limited Dybly AG Eli Lilly and Company F. Hoffmann-La Roche Ltd. GenKyoTex S.A. Gilead Sciences, Inc. Isis Pharmaceuticals, Inc. Jenrin Discovery, Inc. Johnson & Johnson KineMed, Inc. Kowa Company, Ltd. Lead Discovery Center GmbH MedImmune, LLC Merck & Co., Inc. MI.TO. Technology S.r.L. Novartis AG Omeros Corporation OPKO Health, Inc. Otsuka Holdings Co., Ltd. Provid Pharmaceuticals, Inc. Resverlogix Corp. The Medicines Company Therapix Biosciences Ltd Vascular Biogenics Ltd. Vericel Corporation Vitae Pharmaceuticals, Inc.

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Atherosclerosis Overview 11
Therapeutics Development 12
Pipeline Products for Atherosclerosis - Overview 12
Pipeline Products for Atherosclerosis - Comparative Analysis 13
Atherosclerosis - Therapeutics under Development by Companies 14
Atherosclerosis - Therapeutics under Investigation by Universities/Institutes 19
Atherosclerosis - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Atherosclerosis - Products under Development by Companies 25
Atherosclerosis - Products under Investigation by Universities/Institutes 30
Atherosclerosis - Companies Involved in Therapeutics Development 32
Ache Laboratorios Farmaceuticos S/A 32
advanceCor GmbH 33
AFFiRiS AG 34
Arisaph Pharmaceuticals, Inc. 35
Artery Therapeutics, Inc. 36
AstraZeneca Plc 37
Athera Biotechnologies AB 38
AtheroNova Inc. 39
AuraSense Therapeutics, LLC 40
Bayer AG 41
Bridge Bioresearch Plc 42
Campus Technologies Freiburg GmbH 43
Cardax Pharmaceuticals, Inc. 44
ChemoCentryx, Inc. 45
CohBar Inc. 46
DoNatur GmbH 47
Dr. Reddy's Laboratories Limited 48
Dybly AG 49
Eli Lilly and Company 50
F. Hoffmann-La Roche Ltd. 51
GenKyoTex S.A. 52
Gilead Sciences, Inc. 53
Isis Pharmaceuticals, Inc. 54
Jenrin Discovery, Inc. 55
Johnson & Johnson 56
KineMed, Inc. 57
Kowa Company, Ltd. 58
Lead Discovery Center GmbH 59
MedImmune, LLC 60
Merck & Co., Inc. 61
MI.TO. Technology S.r.L. 62
Novartis AG 63
Omeros Corporation 64
OPKO Health, Inc. 65
Otsuka Holdings Co., Ltd. 66
Provid Pharmaceuticals, Inc. 67
Resverlogix Corp. 68
The Medicines Company 69
Therapix Biosciences Ltd 70
Vascular Biogenics Ltd. 71
Vericel Corporation 72
Vitae Pharmaceuticals, Inc. 73
Atherosclerosis - Therapeutics Assessment 74
Assessment by Monotherapy Products 74
Assessment by Target 75
Assessment by Mechanism of Action 78
Assessment by Route of Administration 81
Assessment by Molecule Type 83
Drug Profiles 85
6860766 - Drug Profile 85
AEM-28 - Drug Profile 86
AG-01 - Drug Profile 87
AHRO-001 - Drug Profile 88
AHRO-002 - Drug Profile 90
AHRO-003 - Drug Profile 91
aliskiren fumarate - Drug Profile 92
AM-0010 - Drug Profile 94
anacetrapib - Drug Profile 95
Annexin A-5 - Drug Profile 97
Antisense Oligonucleotide to Inhibit Cide B for Hyperlipidemia and Atherosclerosis - Drug Profile 99
ARI-1778 - Drug Profile 100
Artpep-2 - Drug Profile 101
ATH-03 - Drug Profile 102
ATH-04 - Drug Profile 103
ATH-05 - Drug Profile 104
ATH-06 - Drug Profile 105
AZ-876 - Drug Profile 106
BAY-606583 - Drug Profile 107
BSN-272 - Drug Profile 108
CCX-771 - Drug Profile 109
CCX-872 - Drug Profile 110
CDX-085 - Drug Profile 111
Cell Therapy for Atherosclerosis - Drug Profile 113
CM-7 - Drug Profile 114
COR-2 - Drug Profile 115
CSN-501 - Drug Profile 116
CVX-210H - Drug Profile 117
D-4F - Drug Profile 118
DIAS-2 - Drug Profile 119
DRL-17822 - Drug Profile 120
Drug for Atherosclerosis - Drug Profile 121
Drug to Agonize TLR-4 for Metabolic Disorders, Immunology and Cardiovascular Disease - Drug Profile 122
Drugs for Cardiovascular Diseases - Drug Profile 123
Drugs to Activate TLR3 for Atherosclerosis - Drug Profile 125
Drugs to Antagonize NMDA Receptor for Atherosclerosis - Drug Profile 126
DYB-186 - Drug Profile 127
EP-80317 - Drug Profile 128
evacetrapib - Drug Profile 129
FX-5A - Drug Profile 131
Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile 132
Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile 133
Gene Therapy to Target miR-145 for Atherosclerosis - Drug Profile 134
GKT-136901 - Drug Profile 135
GKT-137831 - Drug Profile 137
GKT-901 - Drug Profile 138
GYY-4137 - Drug Profile 139
Humanin - Drug Profile 141
INV-88 - Drug Profile 142
ISIS-APOARx - Drug Profile 143
ixmyelocel-T - Drug Profile 144
JD-6000 Series - Drug Profile 147
K-312 - Drug Profile 148
K-877 - Drug Profile 149
KM-011 - Drug Profile 150
KRP-206 - Drug Profile 151
LDN-193189 - Drug Profile 152
LPC-01 - Drug Profile 153
MCS-18 - Drug Profile 154
MDCO-216 - Drug Profile 156
MEDI-6012 - Drug Profile 158
melittin - Drug Profile 160
microRNA-30c for Hyperlipidemia and Atherosclerosis - Drug Profile 161
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile 163
Monoclonal Antibody to Inhibit Endothelial Lipase for Atherosclerosis - Drug Profile 165
Nanotherapeutics - Drug Profile 166
Oligonucleotide to Agonize SRB1 for Atherosclerosis and Lymphoma - Drug Profile 167
P-16 - Drug Profile 169
PC-mAb - Drug Profile 170
Peptides to Inhibit Calcineurin for Rheumatoid Arthritis and Atherosclerosis - Drug Profile 172
Protein for Atherosclerosis - Drug Profile 173
Px-102 - Drug Profile 174
Recombinant Protein for Atherosclerosis and Hepatic Steatosis - Drug Profile 176
Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile 178
RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis - Drug Profile 179
RO-6836191 - Drug Profile 180
rPAI-123 - Drug Profile 181
RVX-208 - Drug Profile 182
Small Molecule for Atherosclerosis - Drug Profile 184
Small Molecule for Atherosclerosis - Drug Profile 185
Small Molecule Target GPR176 for Atherosclerosis - Drug Profile 186
Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile 187
Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile 188
Small Molecule to Target GPR132 for Atherosclerosis - Drug Profile 189
Small Molecules for Atherosclerosis - Drug Profile 190
Small Molecules for Atherosclerosis - Drug Profile 191
Small Molecules for Inflammatory Diseases - Drug Profile 192
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 193
Small Molecules to Agonize GPR81 for Atherosclerosis and Obesity - Drug Profile 195
Small Molecules to Antagonize TLR2 and TLR4 for Immune inflammatory Diseases - Drug Profile 196
Small Molecules to Inhibit Chymase for Atherosclerosis - Drug Profile 197
Small Molecules to Inhibit Lipase for Atherosclerosis - Drug Profile 198
SPX-7233801 - Drug Profile 199
Stem Cell Therapy for Atherosclerosis - Drug Profile 200
SYN-20110119RU - Drug Profile 201
Synthetic Peptide for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile 202
Synthetic Peptide to Inhibit F11R for Atherosclerosis - Drug Profile 204
Synthetic Peptides to Activate Apolipoprotein for Atherosclerosis and Inflammation - Drug Profile 206
Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile 207
Vaccine for Atherosclerosis - Drug Profile 209
Vaccine for Atherosclerosis - Drug Profile 210
Vaccine for Atherosclerosis - Drug Profile 211
Vaccine to Target Angiotensin II for Cardiovascular Diseases - Drug Profile 212
VB-201 - Drug Profile 213
VTP-4 - Drug Profile 215
Atherosclerosis - Recent Pipeline Updates 216
Atherosclerosis - Dormant Projects 245
Atherosclerosis - Discontinued Products 254
Atherosclerosis - Product Development Milestones 257
Featured News & Press Releases 257
Appendix 268
Methodology 268
Coverage 268
Secondary Research 268
Primary Research 268
Expert Panel Validation 268
Contact Us 268
Disclaimer 269

List of Tables
List of Tables
Number of Products under Development for Atherosclerosis, H1 2015 19
Number of Products under Development for Atherosclerosis - Comparative Analysis, H1 2015 20
Number of Products under Development by Companies, H1 2015 22
Number of Products under Development by Companies, H1 2015 (Contd..1) 23
Number of Products under Development by Companies, H1 2015 (Contd..2) 24
Number of Products under Development by Companies, H1 2015 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H1 2015 27
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 28
Comparative Analysis by Late Stage Development, H1 2015 29
Comparative Analysis by Clinical Stage Development, H1 2015 30
Comparative Analysis by Early Stage Development, H1 2015 31
Products under Development by Companies, H1 2015 32
Products under Development by Companies, H1 2015 (Contd..1) 33
Products under Development by Companies, H1 2015 (Contd..2) 34
Products under Development by Companies, H1 2015 (Contd..3) 35
Products under Development by Companies, H1 2015 (Contd..4) 36
Products under Investigation by Universities/Institutes, H1 2015 37
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 38
Atherosclerosis - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 39
Atherosclerosis - Pipeline by advanceCor GmbH, H1 2015 40
Atherosclerosis - Pipeline by AFFiRiS AG, H1 2015 41
Atherosclerosis - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015 42
Atherosclerosis - Pipeline by Artery Therapeutics, Inc., H1 2015 43
Atherosclerosis - Pipeline by AstraZeneca Plc, H1 2015 44
Atherosclerosis - Pipeline by Athera Biotechnologies AB, H1 2015 45
Atherosclerosis - Pipeline by AtheroNova Inc., H1 2015 46
Atherosclerosis - Pipeline by AuraSense Therapeutics, LLC, H1 2015 47
Atherosclerosis - Pipeline by Bayer AG, H1 2015 48
Atherosclerosis - Pipeline by Bridge Bioresearch Plc, H1 2015 49
Atherosclerosis - Pipeline by Campus Technologies Freiburg GmbH, H1 2015 50
Atherosclerosis - Pipeline by Cardax Pharmaceuticals, Inc., H1 2015 51
Atherosclerosis - Pipeline by ChemoCentryx, Inc., H1 2015 52
Atherosclerosis - Pipeline by CohBar Inc., H1 2015 53
Atherosclerosis - Pipeline by DoNatur GmbH, H1 2015 54
Atherosclerosis - Pipeline by Dr. Reddy's Laboratories Limited, H1 2015 55
Atherosclerosis - Pipeline by Dybly AG, H1 2015 56
Atherosclerosis - Pipeline by Eli Lilly and Company, H1 2015 57
Atherosclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 58
Atherosclerosis - Pipeline by GenKyoTex S.A., H1 2015 59
Atherosclerosis - Pipeline by Gilead Sciences, Inc., H1 2015 60
Atherosclerosis - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 61
Atherosclerosis - Pipeline by Jenrin Discovery, Inc., H1 2015 62
Atherosclerosis - Pipeline by Johnson & Johnson, H1 2015 63
Atherosclerosis - Pipeline by KineMed, Inc., H1 2015 64
Atherosclerosis - Pipeline by Kowa Company, Ltd., H1 2015 65
Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H1 2015 66
Atherosclerosis - Pipeline by MedImmune, LLC, H1 2015 67
Atherosclerosis - Pipeline by Merck & Co., Inc., H1 2015 68
Atherosclerosis - Pipeline by MI.TO. Technology S.r.L., H1 2015 69
Atherosclerosis - Pipeline by Novartis AG, H1 2015 70
Atherosclerosis - Pipeline by Omeros Corporation, H1 2015 71
Atherosclerosis - Pipeline by OPKO Health, Inc., H1 2015 72
Atherosclerosis - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 73
Atherosclerosis - Pipeline by Provid Pharmaceuticals, Inc., H1 2015 74
Atherosclerosis - Pipeline by Resverlogix Corp., H1 2015 75
Atherosclerosis - Pipeline by The Medicines Company, H1 2015 76
Atherosclerosis - Pipeline by Therapix Biosciences Ltd, H1 2015 77
Atherosclerosis - Pipeline by Vascular Biogenics Ltd., H1 2015 78
Atherosclerosis - Pipeline by Vericel Corporation, H1 2015 79
Atherosclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2015 80
Assessment by Monotherapy Products, H1 2015 81
Number of Products by Stage and Target, H1 2015 83
Number of Products by Stage and Mechanism of Action, H1 2015 86
Number of Products by Stage and Route of Administration, H1 2015 89
Number of Products by Stage and Molecule Type, H1 2015 91
Atherosclerosis Therapeutics - Recent Pipeline Updates, H1 2015 223
Atherosclerosis - Dormant Projects, H1 2015 252
Atherosclerosis - Dormant Projects (Contd..1), H1 2015 253
Atherosclerosis - Dormant Projects (Contd..2), H1 2015 254
Atherosclerosis - Dormant Projects (Contd..3), H1 2015 255
Atherosclerosis - Dormant Projects (Contd..4), H1 2015 256
Atherosclerosis - Dormant Projects (Contd..5), H1 2015 257
Atherosclerosis - Dormant Projects (Contd..6), H1 2015 258
Atherosclerosis - Dormant Projects (Contd..7), H1 2015 259
Atherosclerosis - Dormant Projects (Contd..8), H1 2015 260
Atherosclerosis - Discontinued Products, H1 2015 261
Atherosclerosis - Discontinued Products (Contd..1), H1 2015 262
Atherosclerosis - Discontinued Products (Contd..2), H1 2015 263

List of Figures
List of Figures
Number of Products under Development for Atherosclerosis, H1 2015 19
Number of Products under Development for Atherosclerosis - Comparative Analysis, H1 2015 20
Number of Products under Development by Companies, H1 2015 21
Number of Products under Investigation by Universities/Institutes, H1 2015 26
Comparative Analysis by Clinical Stage Development, H1 2015 30
Comparative Analysis by Early Stage Products, H1 2015 31
Assessment by Monotherapy Products, H1 2015 81
Number of Products by Top 10 Targets, H1 2015 82
Number of Products by Stage and Top 10 Targets, H1 2015 82
Number of Products by Top 10 Mechanism of Actions, H1 2015 85
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 85
Number of Products by Top 10 Routes of Administration, H1 2015 88
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 88
Number of Products by Top 10 Molecule Types, H1 2015 90
Number of Products by Stage and Top 10 Molecule Types, H1 2015 90

Title Date Price
Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report
By QYResearch
The Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Digital Camera Head for Endoscopes industry. The re ...Read More
Apr 2016 $3600.00
China Pharmaceutical Guidebook Series (4) Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Traditional Chinese Medicines and Natural Medicines
By Access China Management Consulting Ltd
The traditional medicines in Orient, especially, the traditional Chinese medicines are always regarded by occidental as mysterious medicines. Until today not only the chemical composition of tradition ...Read More
May 2015 $750.00
Latest Guide to Chinese Pharmaceutical GMP Regulations
By Access China Management Consulting Ltd
China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2012, sales on the Chinese drug market have reached RMB 926.1billion (about US$147 billion) ...Read More
Jul 2015 $750.00
"Acne vulgaris "- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acne vulgaris  - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the disease and ...Read More
Apr 2016 $4950.00
"Acute coronary syndrome(ACS)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute coronary syndrome (ACS) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of th ...Read More
Apr 2016 $4950.00
"Acute heart failure(AHF)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute heart failure (AHF) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the di ...Read More
Apr 2016 $4950.00
"Acute ischemic stroke (AIS)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute ischemic stroke (AIS) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the ...Read More
Apr 2016 $4950.00
"Acute lymphoblastic leukemia (ALL)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute lymphoblastic leukemia (ALL) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview ...Read More
Apr 2016 $4950.00
"Age-related macular degeneration (AMD)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Age-related macular degeneration (AMD) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overv ...Read More
Apr 2016 $4950.00
"Alzheimer’s disease (AD)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the d ...Read More
Apr 2016 $4950.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

Published By :  Global Markets Direct

For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z